Spruce Biosciences Net Income vs. Current Valuation
| SPRB Stock | USD 50.24 0.00 0.00% |
Net Loss | First Reported 2019-03-31 | Previous Quarter -2.1 M | Current Value -8.2 M | Quarterly Volatility 4.5 M |
For Spruce Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Spruce Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Spruce Biosciences Common utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Spruce Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Spruce Biosciences Common over time as well as its relative position and ranking within its peers.
Check out World Market Map. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Spruce Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (84.32) | Revenue Per Share | Quarterly Revenue Growth (0.76) | Return On Assets | Return On Equity |
Understanding Spruce Biosciences Common requires distinguishing between market price and book value, where the latter reflects Spruce's accounting equity. The concept of intrinsic value - what Spruce Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Spruce Biosciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spruce Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Spruce Biosciences Common Current Valuation vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Spruce Biosciences's current stock value. Our valuation model uses many indicators to compare Spruce Biosciences value to that of its competitors to determine the firm's financial worth. Spruce Biosciences Common is rated below average in net income category among its peers. It also is rated below average in current valuation category among its peers . At present, Spruce Biosciences' Net Loss is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Spruce Biosciences' earnings, one of the primary drivers of an investment's value.Spruce Current Valuation vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Spruce Biosciences |
| = | (53.04 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Spruce Biosciences |
| = | 43.9 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Spruce Current Valuation vs Competition
Spruce Biosciences Common is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 524.99 Million. Spruce Biosciences holds roughly 43.9 Million in current valuation claiming about 8% of equities under Health Care industry.
Spruce Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Spruce Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Spruce Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Spruce Biosciences' change in net profit over the period of time. It can combine multiple indicators of Spruce Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 3.6 M | 3.8 M | |
| Operating Income | -50.5 M | -53.1 M | |
| Net Loss | -47.7 M | -50.1 M | |
| Income Before Tax | -47.7 M | -50.1 M | |
| Total Other Income Expense Net | 3.6 M | 3.8 M | |
| Net Loss | -41.6 M | -43.6 M | |
| Net Loss | -47.7 M | -50.1 M | |
| Income Tax Expense | -88.1 K | -83.7 K | |
| Non Operating Income Net Other | 1.8 M | 947.6 K | |
| Interest Income | 3.9 M | 2.6 M | |
| Change To Netincome | 4.2 M | 4.4 M | |
| Net Loss | (88.98) | (93.43) | |
| Income Quality | 1.21 | 0.99 | |
| Net Income Per E B T | 0.91 | 0.81 |
Spruce Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Spruce Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Spruce Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Spruce Biosciences' important profitability drivers and their relationship over time.
Spruce Biosciences Earnings Estimation Breakdown
The calculation of Spruce Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Spruce Biosciences is estimated to be -9.92375 with the future projection ranging from a low of -13.8975 to a high of -5.95. Please be aware that this consensus of annual earnings estimates for Spruce Biosciences Common is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-13.9 Lowest | Expected EPS | -5.95 Highest |
Spruce Biosciences Earnings Projection Consensus
Suppose the current estimates of Spruce Biosciences' value are higher than the current market price of the Spruce Biosciences stock. In this case, investors may conclude that Spruce Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Spruce Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 4 | 1.47% | -14.58 | -9.92375 | -84.32 |
Spruce Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Spruce Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Spruce Biosciences Common predict the company's earnings will be in the future. The higher the earnings per share of Spruce Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Spruce Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Spruce Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Spruce Biosciences should always be considered in relation to other companies to make a more educated investment decision.Spruce Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Spruce Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-10 | 2025-09-30 | -0.215 | -14.58 | -14.365 | 6681 | ||
2025-08-14 | 2025-06-30 | -0.255 | -3.5 | -3.245 | 1272 | ||
2025-05-12 | 2025-03-31 | -0.26 | -0.32 | -0.06 | 23 | ||
2025-03-12 | 2024-12-31 | -0.21 | -0.57 | -0.36 | 171 | ||
2024-11-11 | 2024-09-30 | -0.24 | -0.21 | 0.03 | 12 | ||
2024-08-12 | 2024-06-30 | -0.32 | -0.22 | 0.1 | 31 | ||
2024-05-13 | 2024-03-31 | -0.29 | -0.28 | 0.01 | 3 | ||
2024-03-13 | 2023-12-31 | -0.39 | -0.24 | 0.15 | 38 | ||
2023-11-13 | 2023-09-30 | -0.35 | -0.3 | 0.05 | 14 | ||
2023-08-14 | 2023-06-30 | -0.39 | -0.32 | 0.07 | 17 | ||
2023-05-15 | 2023-03-31 | -0.36 | -0.4 | -0.04 | 11 | ||
2023-03-16 | 2022-12-31 | -0.53 | -0.47 | 0.06 | 11 | ||
2022-11-10 | 2022-09-30 | -0.53 | -0.48 | 0.05 | 9 | ||
2022-08-10 | 2022-06-30 | -0.52 | -0.51 | 0.01 | 1 | ||
2022-05-11 | 2022-03-31 | -0.46 | -0.5 | -0.04 | 8 | ||
2022-03-14 | 2021-12-31 | -0.54 | -0.39 | 0.15 | 27 | ||
2021-11-15 | 2021-09-30 | -0.57 | -0.49 | 0.08 | 14 | ||
2021-08-10 | 2021-06-30 | -0.45 | -0.5 | -0.05 | 11 | ||
2021-05-12 | 2021-03-31 | -0.42 | -0.42 | 0.0 | 0 | ||
2021-03-22 | 2020-12-31 | -0.59 | -0.39 | 0.2 | 33 | ||
2020-11-18 | 2020-09-30 | -0.51 | -12.35 | -11.84 | 2321 | ||
2020-09-02 | 2020-06-30 | 0 | -1.27 | -1.27 | 0 |
Use Spruce Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spruce Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spruce Biosciences will appreciate offsetting losses from the drop in the long position's value.Spruce Biosciences Pair Trading
Spruce Biosciences Common Pair Trading Analysis
The ability to find closely correlated positions to Spruce Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spruce Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spruce Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spruce Biosciences Common to buy it.
The correlation of Spruce Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spruce Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spruce Biosciences Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spruce Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Spruce Biosciences position
In addition to having Spruce Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Target Outcome ETFs Thematic Idea Now
Target Outcome ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Outcome ETFs theme has 86 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Outcome ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
To fully project Spruce Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Spruce Biosciences Common at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Spruce Biosciences' income statement, its balance sheet, and the statement of cash flows.